ISRG vs NKE: Which Is the Better Buy?

Side-by-side comparison of Intuitive Surgical, Inc. and NIKE, Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
Intuitive Surgical, Inc. Β· Healthcare
$451.29
+130.4% upside to fair value
Grade B High Quality
VS
NIKE, Inc. Β· Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
ISRG has more upside to fair value (+130.4%). NKE trades at a lower forward P/E (27.9x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ISRG NKE
Current Price $451.29 $42.62
Fair Value Estimate $1,039.74 $62.00
Upside to Fair Value +130.4% +45.5%
Market Cap $160.3B $63.0B
Forward P/E 53.8x 27.9x
EV / EBITDA 40.5x 20.7x
Price / Sales 15.2x 1.4x
Price / FCF 64.3x 19.4x
Revenue Growth YoY +23.0% -9.8%
Gross Margin 66.3% 42.7%
Operating Margin 30.5% 8.0%
Return on Equity 17.0% 24.4%
Dividend Yield 0% 3.8%
FCF Yield 1.55% 5.2%
Analyst Consensus Strong Buy Buy
Investment Thesis
ISRG β€” Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading healthcare company specializing in robotic-assisted surgery through its flagship da Vinci system, which has established a durable competitive moat with approximately 10,000 systems installed globally and nearly 17 million procedures performed by the end of 2024. The company benefits from a high-quality business model characterized by 85% recurring revenue, st…
NKE β€” NIKE, Inc.
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
Metric ISRG NKE
Zone Low $779.81 $44.00
Zone High $883.78 $50.00
In Buy Zone? Yes Yes
← ISRG Research    NKE Research β†’    All Research